Total Funding
1
Total FundingSeries C raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4023390
CoLucid Pharmaceuticals is a biotechnology company focusing on therapies for central nervous system disorders.
Linda Hogan: Vice President Business DevelopmentPast Role: Care Capital, Executive in Residence
Artthur M. Pappas: Chairman Board of DirectorsPast Role: Glaxo Holdings Plc, Executive Member of Board of Directors
About the Company
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,
chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.
